<DOC>
	<DOCNO>NCT02505997</DOCNO>
	<brief_summary>The purpose study evaluate effect repeat dose oral delafloxacin pharmacokinetic ( PK ) profile single oral dose midazolam .</brief_summary>
	<brief_title>Study Evaluate Effect Delafloxacin Pharmacokinetics Midazolam Healthy Subjects</brief_title>
	<detailed_description>This study evaluate effect repeat dose oral delafloxacin PK profile single oral dose midazolam . The study also evaluate pharmacokinetics , safety , tolerability repeat oral dos delafloxacin healthy male female subject obtain steady state PK profile oral delafloxacin .</detailed_description>
	<mesh_term>Fluoroquinolones</mesh_term>
	<mesh_term>Midazolam</mesh_term>
	<criteria>No clinically important abnormal physical finding . No clinically significant laboratory abnormality . Normal ( abnormal clinically significant ) ECG measurement . Body mass index 18.0 32.0 kg/m2 . Normal ( abnormal clinically significant ) blood pressure pulse rate measurement . methylxanthinecontaining beverage food Nonsmoker Received investigational drug within 8 week administration first dose study drug Female pregnant , positive pregnancy test , breastfeed . Positive test result amphetamine , barbiturate , benzodiazepine , cocaine metabolite , opiate , cannabinoids , methylenedioxymethamphetamine , cotinine , alcohol urine Screening Day −1 . Positive screen test hepatitis B surface antigen , hepatitis C , and/or human immunodeficiency virus antibody . Any surgical medical condition , judgment investigator , might interfere absorption , distribution , metabolism , excretion drug . Used medication ( prescription overthecounter , include health supplement herbal remedy , exception acetaminophen , define exclusion number 8 ) within 2 week ( 4 week drug substance know inhibit induce CYP enzymes and/or Pgp include St. John 's wort [ Hypericum perforatum ] ) 5 halflives ( whichever longer ) first dose study drug . Used oral IV antibiotic within 4 week administration first dose study drug . Routinely chronically use 2 g acetaminophen daily . Performed strenuous activity , sunbathing , and/or contact sport within 96 hour ( 4 day ) entry clinical study site Day −1 , duration study . Donated lose great 400 mL blood 30 day administration first dose study drug . History clinically significant GI disease , gastroenteritis ( vomit diarrhea ) history GI bleeding ( exclude bleed hemorrhoid ) History significant drug allergy History drug alcohol abuse past 2 year</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>